Paris: French drugmaker Sanofi raised its 2017 outlook on the back of strong growth at its consumer health care, vaccines and Genzyme arms in the second quarter, and said it was encouraged by the uptake of a key new eczema drug in the United States. Sanofi said second-quarter net income was down 0.5 per cent at constant exchange rates to 1.7 billion euros ($2 billion) — in line with analysts’ forecasts. Total sales rose 5.5 per cent to 8.66 billion euros.
In March, the US Food and Drug Administration approved Regeneron Pharmaceuticals and Sanofi’s biologic drug for atopic dermatitis — also referred to as eczema — Dupixent, that will sell for a list price of $37,000 for a year of treatment.
